These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31207300)

  • 1. mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.
    Terzuoli E; Costanza F; Ciccone V; Ziche M; Morbidelli L; Donnini S
    Prostaglandins Other Lipid Mediat; 2019 Aug; 143():106344. PubMed ID: 31207300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.
    Li X; Zhao X; Li C; Liu S; Yan F; Teng Y; Feng J; Miao D
    Hum Cell; 2019 Jul; 32(3):360-366. PubMed ID: 31020605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
    Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy.
    Yuan Y; Liu L; Wang Y; Liu S
    Cell Biol Int; 2020 Sep; 44(9):1911-1918. PubMed ID: 32441799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
    Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
    Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
    Kim MS; Kim SH; Yang SH; Kim MS
    PLoS One; 2020; 15(8):e0238155. PubMed ID: 32841278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.
    Li K; Mo C; Gong D; Chen Y; Huang Z; Li Y; Zhang J; Huang L; Li Y; Fuller-Pace FV; Lin P; Wei Y
    Cancer Lett; 2017 Aug; 400():194-202. PubMed ID: 28259822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].
    Gao Z; Zhuang L; Chen Y
    Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):324-31. PubMed ID: 22681918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
    Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
    J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells.
    Liao CH; Tzeng YT; Lai GM; Chang CL; Hu MH; Tsai WL; Liu YR; Hsia S; Chuang SE; Chiou TJ; Wang LM; Whang-Peng J; Yao CJ
    Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32751169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of gefitinib in synergism with thymoquinone
    Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A
    Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.